Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney cancer drug studied in Real-World patients

NCT ID NCT02184416

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how patients with advanced kidney cancer fared when taking the drug axitinib after first trying sunitinib. Researchers did not give any new treatment—they simply observed 554 patients to see how long the drug worked and how long patients stayed on it. The goal was to understand real-world effectiveness outside of a controlled trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

554 people

The number who actually took part.

Started

Oct 2014

Finished

Sep 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will enroll adv/mRCC patients when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient 18 years of age and over * Histologically confirmed diagnosis of advanced/metastatic renal carcinoma (clear cell RCC as well as non-clear cell RCC) with measurable disease according to RECIST 1.1 * Patients being treated with Sutent in 1st line according to the European therapeutic indication and/or being treated with Inlyta in 2nd line according to the European approved therapeutic indication (except post cytokines) * Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: * Patients being treated with cytokines or any other treatment outside of Sutent in 1st line * Patients receiving anti -tumor treatment beyond a second line * Patients already under Sutent, already under Inlyta: enrolment must occur at the beginning of each line of treatment (before or at the first follow up visit at the latest)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic renal cell carcinoma ( MRCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic renal cell carcinoma ( MRCC)

Contacts and locations

Locations

  • AKH - Universitaetsklinik fuer Innere Medizin I

    Vienna, 1090, Austria

  • AKH-Universitat Klinik fur Innere Medizin I

    Vienna, 1090, Austria

  • AKh Linz

    Linz, 4021, Austria

  • ASZ Aalst - Campus Aalst

    Aalst, 9300, Belgium

  • AZ Maria Middelares

    Ghent, 9000, Belgium

  • Algemeen Ziekenhuis Sint-Lucas, Dienst Oncologie

    Ghent, 9000, Belgium

  • C.H.G. Antoine Gayraud, Medecine Interne

    Carcassonne, 11890, France

  • CH Annecy Genevois

    Pringy, 74374, France

  • CH Rene Dubos

    Cergy-Pontoise, 95303, France

  • CHP Saint Gregoire

    Saint-Grégoire, 35760, France

  • CHR Annecy

    Pringy, 74374, France

  • CHU Angers - Hôpital Hôtel Dieu

    Angers, 49100, France

  • CHU Gabriel Montpied

    Clermont-Ferrand, 63003, France

  • Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54511, France

  • Centre Antoine Lacassagne, Service d'Oncologie

    Nice, Alpes-maritimes, 06189, France

  • Centre Catalan Urologie Andrologie

    Cabestany, 66330, France

  • Centre Hospitalier De Bourg En Bresse - Hopital Fleyriat

    Bourg-en-Bresse, 1000, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Hospitalier Lyon Sud - Service d oncologie medicale

    Pierre-Bénite, 69495, France

  • Centre Hospitalier Prive Clairval

    Marseille, 13274, France

  • Centre Hospitalier Prive Saint Gregoire

    Saint-Grégoire, 35768, France

  • Centre Hospitalier Sud Reunion

    Saint-Pierre-des-Corps, 97449, France

  • Centre Hospitalier d'Auxerre

    Auxerre, 89011, France

  • Centre Hospitalier de Longjumeau

    Longjumeau, 91160, France

  • Centre Hospitalier de Pau

    Pau, 64000, France

  • Centre Hospitalier du Marechal Juin

    Valence, 26000, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Rene Gauducheau - Service Oncologie Medicale

    Saint-Herblain, 44805, France

  • Centre d'Oncologie de Gentilly

    Nancy, 54100, France

  • Centre d'Oncologie du Parc

    Dijon, 21000, France

  • Centre d'Oncologie et de Radiotherapie du pays Basque

    Bayonne, 64100, France

  • Centre d'Oncology de Gentilly

    Nancy, 54100, France

  • Centre de Radiothérapie,

    Strasbourg, 67010, France

  • Centro Médico

    Vigo, 36211, Spain

  • Centro Sanitario Hospital Universitario y Politecnico La Fe

    Valencia, 46026, Spain

  • Christie Hospital NHS Trust

    Manchester, M20 4BX, United Kingdom

  • Cl Armoricaine Radiologie / Radiotherapie

    Saint-Brieuc, 22015, France

  • Cl du Docteur Calabet / Cromg

    Agen, 47000, France

  • Clinique Bordeaux Tivoli Ducos

    Bordeaux, 33000, France

  • Clinique Clement Drevon

    Dijon, 21000, France

  • Clinique Clémentville - Oncologie

    Montpellier, 34070, France

  • Clinique Sainte Marguerite

    Hyères, 83400, France

  • Clinique St Pierre - Oncologie

    Ottignies, 1340, Belgium

  • Clinique de la Sauvegarde

    Lyon, 69337, France

  • Clinique les Dentellieres

    Valenciennes, 59300, France

  • Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera

    A Coruña, 15006, Spain

  • Consorcio Hospitalario Parc Tauli

    Sabadell, Barcelona, 08208, Spain

  • Consultant Oncologist

    Cheltenham, Gloustershire, GL53 7AN, United Kingdom

  • Department of Academic Oncology

    Cottingham, HU16 5JQ, United Kingdom

  • Department of Cancer Medicine

    Dundee, Tayside, DD1 9SY, United Kingdom

  • Divisione di Oncologia Medica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola (FC), 47014, Italy

  • Divisione di Oncologia, AORN Antonio Cardarelli

    Naples, 80131, Italy

  • General Hospital of Chest Diseases of Athens "Sotiria"

    Athens, 11527, Greece

  • Groupe Hospitaier Sud Reunion

    Saint-Pierre, 97410, France

  • Groupe Hospitalier Intercommunal le Raincy Montfermeil

    Montfermeil, 93370, France

  • H. U. de Vigo- Hospital Álvaro Cunqueiro/Servicio de Oncologia Medica

    Vigo, 36312, Spain

  • Hopital Belle-Isle

    Metz, 57045, France

  • Hopital Clinique Claude-Bernard

    Metz, 57072, France

  • Hopital Dupuytren - Oncologie Medicale

    Limoges, 87042, France

  • Hopital FOCH

    Suresnes, 92151, France

  • Hopital Georges Pianta

    Thonon-les-Bains, 74203, France

  • Hopital Jean BERNARD - Tours - 7eme etage

    Valenciennes, 59300, France

  • Hopital Nord

    Marseille, 13915, France

  • Hopital Prive Sainte Marie

    Chalon-sur-Saône, 71100, France

  • Hopital Sainte Musse

    Toulon, 83000, France

  • Hopital Timone Adultes

    Marseille, 13385, France

  • Hopital de Hautepierre-Service Oncologie at Hematologie

    Strasbourg, 67098, France

  • Hopital prive La Louviere

    Lille, 59042, France

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, 08036, Spain

  • Hospital Clinico San Carlos

    Madrid, 28040, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007, Spain

  • Hospital General Universitario de Alicante

    Alicante, 03010, Spain

  • Hospital General Yague

    Burgos, 09071, Spain

  • Hospital Infanta Leonor

    Madrid, 28031, Spain

  • Hospital Morales Meseguer

    Murcia, 30008, Spain

  • Hospital Principe de Asturias

    Alcalá de Henares, 28805, Spain

  • Hospital Sant Pau

    Barcelona, 08003, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario de Canarias

    Santa Cruz de Tenerife, 38320, Spain

  • Hospital Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hospital Virgen de La Salud

    Toledo, 45004, Spain

  • Hospital de Leon

    León, 24071, Spain

  • Hospital de Navarra

    Pamplona, Navarre, 31008, Spain

  • Hôpital Saint-André

    Bordeaux, 33075, France

  • Hôpital Universitaire Carémeau

    Nîmes, 30029, France

  • IRCC Oncologia Medica

    Candiolo (TO), 10060, Italy

  • IRCCS Policlinico San Matteo

    Pavia, 27100, Italy

  • Imeldaziekenhuis

    Bonheiden, 2820, Belgium

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut Catala Oncologia - Hospital Universitari de Girona Dr Josep Trueta

    Girona, 17007, Spain

  • Institut Jean Godinot

    Reims, 51056, France

  • Institut Sainte Catherine, Department Oncologie, Medecine Interene

    Avignon, 84082, France

  • Istituto Nazionale Tumori, Oncologia Medica B

    Milan, 20100, Italy

  • Istituto per lo Studio e la Cura dei Tumori Fondazione Pascale

    Naples, 80131, Italy

  • Kent & Canterbury Hospital

    Canterbury, KENT, CT1, United Kingdom

  • Krankenhaus Oberwart

    Oberwart, 7400, Austria

  • Krankenhaus der Barmherzigen Schwestern Linz Abteilung fuer Urologie

    Linz, A-4010, Austria

  • Landeskrankenhaus Bregenz

    Bregenz, A-6900, Austria

  • Pole Sante Republique

    Clermont-Ferrand, 63050, France

  • Polyclinique de Francheville

    Périgueux, 24000, France

  • Pôle Hospitalier Mutualiste

    Saint-Nazaire, 44600, France

  • Royal Marsden Hospital, Royal Marsden NHS Foundation Trust

    London, SW3 7JJ, United Kingdom

  • Royal Surrey County Hospital

    Guildford, Surrey, GU2 7XX, United Kingdom

  • Royal United Hospital Bath NHS

    Bath, BA1 3NG, United Kingdom

  • Salud Hospital Universitario Dr. Peset

    Valencia, 46017, Spain

  • Servicio de Oncologia Medica

    Madrid, 28041, Spain

  • Sozialmedizinisches Zentrum Ost

    Vienna, 1220, Austria

  • Universitasklinik für Urologie und Andrologie

    Salzburg, A-5020, Austria

  • Viecuri Medical Centre

    BL Venlo, 5912, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.